Effector and central memory T helper 2 cells respond differently to peptide immunotherapy by Mackenzie, Karen J. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effector and central memory T helper 2 cells respond differently
to peptide immunotherapy
Citation for published version:
Mackenzie, KJ, Nowakowska, DJ, Leech, MD, McFarlane, A, Wilson, C, Fitch, PM, O'connor, RA, Howie,
SEM, Schwarze, J & Anderton, SM 2014, 'Effector and central memory T helper 2 cells respond differently
to peptide immunotherapy' Proceedings of the National Academy of Sciences, vol. 111, no. 8, pp. E784-93.
DOI: 10.1073/pnas.1316178111
Digital Object Identifier (DOI):
10.1073/pnas.1316178111
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Proceedings of the National Academy of Sciences
Publisher Rights Statement:
Freely available online through the PNAS open access option.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Effector and central memory T helper 2 cells respond
differently to peptide immunotherapy
Karen J. Mackenziea, Dominika J. Nowakowskaa,b,1, Melanie D. Leecha,b,1, Amanda J. McFarlanea, Claire Wilsonc,
Paul M. Fitcha,d, Richard A. O’Connora,b, Sarah E. M. Howiea, Jürgen Schwarzea,d, and Stephen M. Andertona,b,2
aMedical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom; bCentre for Immunity, Infection,
and Evolution, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom; cNational Health Service Lothian, Simpson Centre for Reproductive Health,
Edinburgh EH16 4SA, United Kingdom; and dChild Life and Health, University of Edinburgh, Edinburgh EH9 1UW, United Kingdom
Edited* by Philippa Marrack, Howard Hughes Medical Institute, National Jewish Health, Denver, CO, and approved January 22, 2014 (received for review
August 27, 2013)
Peptide immunotherapy (PIT) offers realistic prospects for the
treatment of allergic diseases, including allergic asthma. Much is
understood of the behavior of naive T cells in response to PIT.
However, treatment of patients with ongoing allergic disease
requires detailed understanding of the responses of allergen-
experienced T cells. CD62L expression by allergen-experienced
T cells corresponds to effector/effector memory (CD62Llo) and cen-
tral memory (CD62Lhi) subsets, which vary with allergen exposure
(e.g., during, or out with, pollen season). The efficacy of PIT on
different T helper 2 (Th2) cell memory populations is unknown. We
developed a murine model of PIT in allergic airway inflammation
(AAI) driven by adoptively transferred, traceable ovalbumin-expe-
rienced Th2 cells. PIT effectively suppressed AAI driven by unfrac-
tionated Th2 cells. Selective transfer of CD62Lhi and CD62Llo Th2
cells revealed that these two populations behaved differently
from one another and from previously characterized (early dele-
tional) responses of naive CD4+ T cells to PIT. Most notably, aller-
gen-reactive CD62Llo Th2 cells were long-lived within the lung
after PIT, before allergen challenge, in contrast to CD62Lhi Th2
cells. Despite this, PIT was most potent against CD62Llo Th2 cells
in protecting from AAI, impairing their ability to produce Th2 cyto-
kines, whereas this capacity was heightened in PIT-treated CD62Lhi
Th2 cells. We conclude that Th2 cells do not undergo an early
deletional form of tolerance after PIT. Moreover, memory Th2 sub-
sets respond differently to PIT. These findings have implications for
the clinical translation of PIT in different allergic scenarios.
Specific immunotherapy involves therapeutic delivery of adisease-relevant antigen to induce tolerance (particularly of
CD4+ T cells) toward that antigen (1, 2). It represents a realistic
and potentially disease-modifying therapeutic approach for the
treatment of allergic and autoimmune diseases with strong CD4+
T-cell components to their pathogenesis, such as allergic asthma
(3–5). Traditional immunotherapy, using whole-protein antigens,
is associated with the risk of severe allergic reactions, particularly
anaphylaxis, in patients harboring allergen-reactive IgE (6, 7).
Peptide immunotherapy (PIT) obviates this risk because it uses
short synthetic peptides containing known T-cell epitopes, but
not conformational antibody epitopes, thereby targeting disease-
driving CD4+ T cells while avoiding IgE binding (8, 9).
In animal studies, PIT can effectively reduce or prevent CD4+
T-cell–driven diseases (10–15). Encouraging findings have also
been reported in allergic patients (16–20). However, reduced
disease severity is not universal, and limitations in our un-
derstanding of the workings of PIT are impeding clinical trans-
lation. Mechanistic murine PIT studies have been advanced
through the use of traceable populations of T-cell receptor
(TCR) transgenic T cells. PIT is highly effective in silencing
“naive” T cells whose first encounter with their cognate antigen
is at the point of tolerogenic peptide application (21, 22). This is
different from the clinical setting where established T-cell–
driven pathology, by definition, presents with an increased fre-
quency of antigen-experienced T cells (23). We, and others, have
previously shown that application of tolerogenic peptide induces
naive CD4+ T cells to enter a brief but abortive phase of pro-
liferation that is followed by their wide-scale apoptotic deletion
(21, 22, 24). This is most likely the result of insufficient cos-
timulation from the antigen-presenting cell in the absence of in-
nate immune triggers (21, 22, 24). However, several characteristics
of antigen-experienced T cells hint that they may not necessarily
respond to PIT in the same way. First, they have lower cos-
timulation requirements (25, 26) that may make them less sus-
ceptible to deletion in response to costimulation deprivation in
the tolerogenic setting. Antigen-experienced T cells can be phe-
notypically classified into effector and memory T-cell populations,
the latter being subdivided into effector memory T cells (Tem)
and central memory T cells (Tcm) (27, 28). Importantly, the
phenotype and frequency of allergen-reactive T cells can vary,
depending on the presence or absence of allergen exposure (e.g.,
perennial vs. seasonal allergy) (29–31). In addition, the pheno-
type of T cells in the end organ (e.g., the lung) may differ from
those in peripheral blood (32–34). These complexities could
have a major impact upon the clinical response to PIT and have
not previously been addressed.
Here, we developed a model to study the effects of PIT upon
Th2-polarized TCR transgenic cells driving allergic airway in-
flammation (AAI). PIT effectively reduced AAI, despite the
allergen-experienced nature of the eliciting Th2 cells. Further-
more, PIT was most potent against AAI driven by CD62Llo Th2
cells (a phenotype associated with effector and Tem) compared
with CD62Lhi Th2 cells (associated with Tcm) (27, 28). Importantly,
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CD62Llo and CD62Lhi Th2 cells showed markedly distinct be-
havior in response to PIT, both in comparison with one another
and compared with the known behavior of naive T cells. Notably,
a sizeable population of PIT-treated CD62Llo cells persisted
long-term within the lung following PIT, in contrast to CD62Lhi
cells. Whereas PIT led to diminished Th2 cytokine production at
the time of airway challenge with allergen in CD62Llo cells, this
effect of PIT was not seen in CD62Lhi cells, which therefore
retained pathogenic activity. The composition of Th2 cell sub-
populations at the time of PIT is thus an important additional
consideration in respect to clinical translation.
Results
A Th2 Cell Transfer Model of Chicken Egg Ovalbumin-Driven Allergic
Airway Inflammation. We established a model of AAI driven by
traceable (CD45.1+) Th2 cells, using OT-II TCR transgenic mice
(35) as a source of T cells recognizing the 323–339 peptide of
chicken egg ovalbumin (pOVA). In vitro activation of OT-II T
cells by pOVA under Th2-polarizing conditions generated a
GATA-3–expressing T-cell population that produced high levels
of IL-5 and IL-13 upon restimulation with OVA, compared with
naive OT-II T cells (Fig. 1A). Transfer of these Th2-polarized
OT-II cells, followed by intratracheal (i.t.) challenge with OVA
(Fig. 1A), induced AAI, as evidenced by cellular infiltration
around airways and blood vessels and goblet cell formation (Fig.
1B). An increase in total cells and eosinophils was evident within
the bronchoalveolar lavage (BAL) (Fig. 1C). These pathological
changes required OVA in the i.t. challenge and could not be
elicited if naive OT-II T cells were transferred (Fig. 1 B and C).
Flow cytometry identified transferred CD45.1+ cells within the
lung (Fig. 1D). Of note, low numbers of Th2 cells, but not naive
T cells, were evident in the absence of OVA i.t. challenge, but
both the number and the frequency of Th2 cells were signifi-
cantly increased following OVA challenge (Fig. 1D). This model
therefore allowed us to relate numbers, phenotype, and function
of preformed Th2 cells in the lung to their pathogenic activity
(AAI), in the presence or absence of PIT.
PIT Suppresses AAI Driven by Preexisting Th2 Cells.Naive OT-II cells
are sensitive to PIT when pOVA is administered i.v. in PBS (21,
22, 24). We assessed therapeutic efficacy of PIT in AAI by ad-
ministration of pOVA 2 d after Th2 cell transfer and 4 d before
i.t. challenges (Fig. 2A). This PIT regimen led to reductions in
cellular infiltration of the lungs, goblet cells in the airways, BAL
eosinophilia, and IL-13 in BAL (Fig. 2 B–E). The total numbers
of OT-II cells in both the lung and the spleen were increased by
OVA challenges in the absence of PIT (Fig. 2F). In PIT-treated
mice, however, numbers of OT-II cells following OVA i.t. chal-
lenge were not significantly different from those seen in PBS-
challenged control mice (Fig. 2F). We therefore conclude that
PIT is effective at diminishing the AAI-inducing function of al-
lergen-experienced Th2 cells.
PIT Drives Th2 Cell Accumulation in the Lung Before Allergen
Challenge. We, and others, have previously demonstrated that
the effectiveness of PIT upon naive OT-II cells predominantly
involves a deletional effect, which is evident 4 d after PIT (21, 22,
36). The data in Fig. 2F highlighted reduced numbers of trans-
ferred Th2 cells after airway challenge in lungs of mice protected
from AAI by PIT. The simplest explanation for this was there-
fore that, as with naive T cells, PIT drives the rapid deletion of
transferred Th2 cells. However, assessment of transferred OT-II
Th2 cell numbers at the time of first i.t. challenge (4 d after PIT,
experimental protocol in Fig. 3A) revealed a widespread increase
in number and frequency of OT-II cells in spleen, lymph nodes,
Fig. 1. A Th2 transfer model of OVA-driven allergic airway inflammation. (A) IL-5 and IL-13 production by naive (□) and Th2-polarized (■) CD4+ OT-II cells in
response to OVA and experimental design for AAI using transfer of 4 × 106 naive or Th2-polarized OT-II cells (seeMaterials and Methods for dose of OVA). (B)
Day 9 analysis of H&E and PAS. (C) Differential BAL cell counts. (D) The percentage of OT-II cells in the CD4+ population and the total number of OT-II cells in
the left lung lobe. Data represent one of two experiments giving consistent results. n ≥ 3, **P ≤ 0.01, ***P ≤ 0.001 vs. all other groups.
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and lung (Fig. 3 B and C). Of particular note was the significant
increase in the percentage of OT-II cells in the lung CD4+
population, compared with that in distal lymph nodes and spleen
(Fig. 3C). Importantly, this difference was most pronounced
after PIT (Fig. 3C).
Our data thus far provided an intriguing scenario in which the
protective effects of PIT against Th2-driven AAI (Fig. 2 B–E)
were associated with ultimately reduced numbers of OT-II cells
after allergen challenge (Fig. 2F), despite a striking initial en-
richment of these cells in the lungs immediately after PIT and
before allergen challenge (Fig. 3C). Thus, PIT promotes accu-
mulation of allergen-reactive T cells within the lung, but these
have substantially impaired pathogenic activity in this relatively
compressed model (4 d between exposure to PIT and first airway
challenge).
We next sought to understand how long this population of
PIT-exposed T cells would persist within the lung. Moreover, given
the possible distinct roles for Tem and Tcm in maintaining memory
in the presence or absence of allergen exposure, we considered it
important to determine whether these two memory populations
might behave differently, either (i) in their colonization of and
persistence in the lung following PIT or (ii) in their functional/
pathogenic impairment following PIT. Separation of putative
Tem and Tcm populations was possible because, although Th2-
polarized OT-II cells on the day of adoptive transfer were all
CD44hi, they consistently displayed a heterogeneous CD62L
profile, including both high- and low-CD62L expressors (Fig. 4A).
These two profiles are associated with Tem (CD44hiCD62Llo) or
Tcm (CD44hiCD62Lhi) (27). The presence of antigen-experienced
adoptively transferred T cells in nonlymphoid organs is well docu-
mented (37, 38), as is the preference for CD62Llo cells to home
to nonlymphoid tissues such as the lung, because of the require-
ment for CD62L expression to facilitate entry into lymph nodes
(32, 33, 39). We therefore predicted that the cells that accumulated
in the lung after PIT were derived from the CD62Llo fraction.
PIT-Treated CD62Llo Th2 Cells Persist Long-Term in the Lung. OT-II
Th2 cells were FACS sorted into CD44hiCD62Llo and CD44hi
CD62Lhi populations and transferred individually before PIT (Fig.
4A). To compare the longevity of each population, mice were
culled 26 d after cell transfer and frequency and number of
transferred OT-II cells determined. Even in the absence of al-
lergen airway challenge, the lungs of mice that had received
CD62Llo Th2 cells contained markedly elevated frequencies of
transferred cells, to the extent that there were greater numbers
of OT-II cells in the lung than in the spleen at 24 d after PIT.
This was not the case for CD62Lhi transfer, although an OT-II
accumulation in the lung was evident following PIT (Fig. 4B).
There were no differences in the percentage of OT-II cells in the
CD4+ population or in total OT-II cell number, in spleen or lymph
nodes in any of the groups, regardless of PIT treatment (Fig. 4B).
The greater accumulation of transferred CD62Llo cells in the lungs
was not, therefore, because of an inherent improved viability.
We concluded that, unlike the previously reported effects of
PIT upon naive OT-II cells, there was no evidence for depletion
of transferred CD62Lhi or CD62Llo populations from the lym-
phoid organs. Moreover, the numbers of transferred cells in the
lung were enriched following PIT. This effect was particularly
pronounced for the transferred CD62Llo population. It therefore
became even more important to determine how these differences
influenced subsequent susceptibility to AAI following allergen
airway challenge.
PIT-Treated CD62Llo Th2 Cells Are Least Pathogenic upon Allergen
Airway Challenge. The experimental protocol described in Fig. 4
was extended to include airway challenge with OVA, com-
mencing at day 26 (Fig. 5A). Despite having the highest numbers
Fig. 2. PIT suppresses AAI driven by preexisting Th2 cells. (A) Experimental design (seeMaterials and Methods for doses of pOVA and OVA). (B) H&E and PAS
stains of lung sections. (C) Quantification of goblet cells. (D) Differential BAL cell counts. (E) Concentrations of IL-13 in BAL fluid. (F) Total OT-II numbers in left
lung lobes and spleens. “No PIT”: mice received PBS alone. Data are pooled from two experiments; consistent data were found in three or more experiments.
n ≥ 6, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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of transferred Th2 cells in the lung at the time of challenge (Fig.
4B), mice that received CD62Llo cells and PIT did not develop
aggravated AAI. Far from it, they showed the least severe AAI in
terms of histological appearance (Fig. 5B), with comprehensive
reductions in AAI parameters—namely the percentage of goblet
cells, total BAL cells, BAL eosinophilia, and suppression of IL-5/
IL-13 cytokine production by OT-II cells in the lungs (Fig. 5 B–D
and F). In contrast, the effectiveness of PIT against CD62Lhi
cells was limited, with reductions in AAI parameters restricted to
IL-13 concentration in BAL and the percentage of OT-II cells
producing IL-5 and/or IL-13 in the lung (Fig. 5 E and F). Although
there was a tendency for CD62Lhi Th2 cells to be more pathogenic
than CD62Llo Th2 cells upon allergen challenge [e.g., in terms of
BAL eosinophilia (Fig. 5D)], this was not consistent across all
parameters [e.g., in terms of the percentage of goblet cells (Fig.
5C)], enabling us to conclude that PIT was most potent against
CD62Llo Th2 cells. There were no differences in the percentage
of OT-II cells expressing Foxp3 between groups (<6% in all).
PIT was associated with a reduced frequency of OT-II cells
following airway challenge in lung, mediastinal lymph nodes
(mLN), and spleen following allergen challenge, compared with
non-PIT controls, regardless of whether mice had received
CD62Llo or CD62Lhi OT-II cells (Fig. 5G).
Both CD62Lhi and CD62Llo Cells Accumulate in the Lung, but PIT-
Treated CD62Llo Cells Have More Stable Persistence. To better un-
derstand the PIT-induced changes in the transferred CD62Lhi
and CD62Llo cells, we compared these populations at additional
time points following PIT administration and allergen challenge
for their accumulation within the lung, their proliferative state
(by Ki-67 staining), and their functional capacity (by intracellular
cytokine staining), focusing particularly on the lung. Our pre-
diction was that CD62Llo cells would preferentially enter the
lung before PIT treatment. This proved incorrect, because sim-
ilar numbers of transferred CD62Lhi cells were also evident in
the lung after 2 d (the time of PIT administration) (Fig. 6).
However, in PBS-treated controls, numbers and frequencies of
transferred CD262Llo cells remained relatively stable in the lung
from this time to the point of allergen challenge (day 26 post-
transfer), whereas some attrition in the transferred CD62Lhi
population could be seen. Both transferred populations showed
elevated numbers and frequencies in the lung at day 6, 4 d after
PIT, but the greatest increase was seen in the transferred
CD62Lhi cells. Thereafter, PIT-exposed CD62Lhi cells declined
in the lung, whereas PIT-exposed CD62Llo cells were maintained
at elevated frequencies and increased in numbers to the point of
the first airway challenge (day 26).
PIT Conditions for the Loss of Transferred Th2 Cells in the Lung upon
Airway Challenge with Allergen. Assessment 24 h after the second
airway challenge (day 30) revealed no rise in frequency of OT-II
cells in the lungs of mice that received CD62Llo cells without PIT
(this was only seen on day 34, after the third airway challenge)
(Fig. 6). In contrast, frequencies of OT-II cells in the lungs of
mice that received CD62Lhi cells without PIT were beginning
to rise after the second airway challenge. Regardless of their
CD62L status, frequencies of PIT-exposed transferred cells had
declined after the second airway challenge (markedly so in the case
Fig. 3. PIT drives Th2 cell accumulation in the lung before allergen chal-
lenge. (A) Experimental design. (B) The total number of OT-II cells in spleen
and lung. (C) The percentage of OT-II cells in the CD4+ population in spleen,
para-aortic and inguinal lymph nodes (LN), and lung. No PIT: mice received
PBS alone. Data are from one experiment and are representative of findings
from two or more experiments giving consistent results. n = 4, **P ≤ 0.01,
***P ≤ 0.001.
Fig. 4. Peptide immunotherapy triggers a preferential, and long-lived, ex-
pansion of CD44hiCD62Llo Th2 cells in the lung. (A) Experimental design.
Mice received 2 × 106 CD4+CD44hiCD62Llo (CD62Llo) or CD4+CD44hiCD62Lhi
(CD62Lhi) Th2 cells (seeMaterials and Methods for doses of pOVA and OVA).
(B) The percentages and total numbers of OT-II cells in spleen, inguinal and
para-aortic lymph nodes (LN), and whole lung. Data are pooled from
two experiments, giving consistent results. n ≥ 5, *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001.
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of PIT-treated CD62Llo cells). This decline in PIT-treated CD62Llo
cells continued to the final time point, after the third airway
challenge (day 34), but frequencies of OT-II cells in mice that
received CD62Lhi cells and PIT appeared to stabilize or even in-
crease by this point.
Proliferative Capacity Is Greater in Transferred CD62Lhi Cells than in
CD62Llo Cells upon Airway Challenge. As would be expected, both
transferred populations showed evidence of maintained prolifer-
ation 2 d after transfer (Fig. 7). Ki-67 staining 4 d after PIT was in-
dicative of TCR stimulation, but by day 13 after transfer (11 d after
PIT), few cells were in cell cycle, indicating that the more pro-
nounced long-term persistence of CD62Llo cells in the lung was
not due to a greater/longer proliferative capacity. Following the
second airway challenge (day 30), Ki-67 staining was evident in all
transferred populations, but the frequencies of Ki-67+ cells were
highest in non–PIT-exposed CD62Lhi cells (Fig. 7), consistent with
these cells showing themost elevated frequencies at days 30 and 34,
relative to day 26 (Fig. 6). Frequencies of Ki-67+ PIT-treated cells
on day 30 were below those seen for non–PIT-treated cells (Fig. 7),
with the lowest frequencies seen in the PIT-treated CD62Llo pop-
ulation, consistent with this group having the poorest representation
of transferred cells in the lung at day 34 (Figs. 5 and 6).
PIT-Exposed CD62Lhi Cells Maintain a Heightened Capacity for Cytokine
Production. The transferred CD62Lhi population showed robust
Th2 cell function in the lung after airway challenge (Fig. 5). To be
of relevance to the increased pathology seen in mice receiving
these cells, this feature should be evident earlier, at the time
of airway challenge. We therefore assessed Th2 cytokine (IL-
13 and/or IL-5) production following PIT and at the point of
allergen challenge (Fig. 8A). In PBS-treated controls at day 6,
cytokine production was highest among CD62Llo cells, con-
sistent with a predicted strong effector function. In contrast, by
the time of airway challenge, cytokine production was at least
as evident in the CD62Lhi group as in the CD62Llo group in the
absence of PIT. At days 6 and 13, PIT-exposed CD62Lhi cells
showed elevated cytokine production relative to controls. This
was not seen in PIT-exposed CD62Llo cells and, by the time of
airway challenge, these PIT-exposed cells showed lower fre-
quencies of cytokine-expressing cells than their control group.
We did not find any evidence for loss of GATA-3 expression in
the transferred CD62Llo cells (whether they had been exposed
to PIT or not) that could account for their poorer production
of Th2 cytokines (Fig. 8B). Importantly, at the time of first airway
challenge (day 26) CD62Lhi cells showed strong production of
IL-5 and IL-13 whether they had been previously exposed to
PIT or not (Fig. 8A). We conclude that, whereas transferred
CD62Llo cells that are exposed to PIT have diminished Th2
effector cytokine production in the lung by the time of allergen
challenge, this key feature of pathogenic activity is actually
prompted, and sustained, in transferred CD62Lhi cells respond-
ing to PIT.
Fig. 5. PIT-treated CD62Llo Th2 cells are least pathogenic upon allergen airway challenge. (A) Experimental design. Mice received 2 × 106 CD62Llo or
CD62Lhi Th2 cells as in Fig. 4. (B and C ) H&E (B) and PAS (C ) staining of lung sections and the percentage of goblet cells in the airways. (D) Differential
BAL cell counts. (E ) Concentrations of IL-13 in BAL fluid. (F ) The percentage of IL-5+ and/or IL-13+ OT-II cells in the left lung lobe after overnight culture
in the presence of pOVA. (G) The percentage of OT-II cells in the CD4+ population and the total number of OT-II cells in spleen, mediastinal LN (mLN), and left
lung lobe. No PIT: mice received PBS alone. Data are pooled from two experiments, giving consistent results. n ≥ 9, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001;
ns, not significant.
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Discussion
True mechanistic understanding of the effects of PIT necessitates
assessment in the context of antigen-experienced, rather than
naive, T cells, because the overriding aim of allergen immuno-
therapy is to combat established allergic immune responses (40).
Previous work providing PIT between airway challenges suggested
therapeutic benefit in experimental models in which allergen-
experienced T cells should predominate (15). Here we have fol-
lowed the fates of defined, allergen-experienced Th2 populations
to show definitively that PIT can be highly effective in controlling
the pathogenic activity of such cells in AAI. We show that the
effects of PIT upon Th2 cells differ substantially from the early
deletional response known to occur with naive CD4+ T cells
(including when we have used the same OT-II TCR transgenic
cells and PIT regimen) (21). Beyond this, we show that the be-
havior of Th2 cells in response to PIT varies with their level of
CD62L expression.
Both the CD62Llo and the CD62Lhi populations we trans-
ferred contained cells that were long-lived, indicative of memory
function. Our data indicate that, although both transferred
CD62Lhi and CD62Llo Th2 cells can infiltrate the lung and un-
dergo rapid proliferation therein in response to PIT, PIT-treated
CD62Llo cells have a greater capacity to persist long-term in the
lung. However, by the time of airway allergen challenge, these
persisting PIT-treated CD62Llo cells have a poorer proliferative
capacity and poorer Th2 cytokine-producing capacity than their
PIT-treated CD62Lhi counterparts. Our data indicate that, rather
than driving an immediate apoptotic deletion (as has been reported
for naive OT-II cells), PIT conditions the transferred Th2 cells for
deletion (presumably via apoptosis) upon subsequent exposure
to allergen within the lung. This was particularly the case for the
transferred CD62Llo population. This, together with the emphatic
PIT-induced suppression of Th2 cytokine production by CD62Llo
cells at the time of allergen challenge, means that PIT is most po-
tent against these cells. The greater proliferative activity and cyto-
kine-producing capacity of PIT-treated CD62Lhi cells allows them
to retain greater pathogenic activity. We believe the observation
that this Tcm population can be triggered to gain effector function
(Th2 cytokine production) in response to PIT is also a novel finding.
Tcm can make use of high CD62L expression to traffic into
lymph nodes across high endothelial venules, whereas CD62Llo
Tem more readily access the tissues. The paradigm is that Tem
respond to antigenic challenge with rapid production of effector
cytokines but only limited proliferative capacity (27, 28). Tcm
show low effector cytokine production compared with Tem, but
their strong proliferative capacity upon reencountering antigen
generates new effector T cells (27, 28). Tcm, rather than Tem, are
thought to contribute more to the memory pool in the long-term
(27, 41–43). The CD62Lhi cells we transferred showed a greater
ability to enter the cell cycle following allergen challenge to the
lung (whether they had been exposed to PIT or not), consistent
with the Tcm paradigm. However, it is somewhat surprising that,
in our study, it was the transferred CD62Llo cells rather than the
CD62Lhi cells that showed greater long-term persistence in the
lung after exposure to PIT. However, in some instances, CD8+ Tem
are capable of proliferation and the establishment of new memory
cells (44). This may support the durable nature of CD62Llo cells
seen here after PIT; why CD62Lhi cells do not also behave in this
way remains to be determined.
In contrast to their relatively poor proliferative capacity, Tem,
by definition, should possess a greater capacity to produce
effector cytokines than Tcm. This was borne out by the greater
ability of the transferred CD62Llo Th2 cells than their CD62Lhi
counterparts to produce IL-5 and/or IL-13 in the absence of PIT
Fig. 6. The effects of PIT on transferred CD62Llo or CD62Lhi Th2 populations. Mice received 2 × 106 CD4+CD44hiCD62Llo (CD62Llo) or CD4+CD44hiCD62Lhi
(CD62Lhi) Th2 cells (seeMaterials and Methods for doses of pOVA and OVA). (A and B) The percentage of OT-II cells in the CD4+ population (Left) and the total
numbers (Right) of CD45.1+ OT-II cells in (A) lung and (B) spleen were determined by flow cytometry on the days shown on the x axis. Dotted vertical lines
show days of PIT and airway challenge. Solid symbols, PIT; open symbols, no PIT. Error bars show SEM. Data were collated from seven experiments with 3–12
mice per group, per time point. Note that total numbers were not available for the lung on day 34 as only left lung lobes were prepared for flow cytometry to
allow concomitant histological processing of the remaining lung tissue.
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at day 6. The marked difference in effector cytokine capacity in
response to PIT—a gradual decline in transferred CD62Llo cells
vs. a rapid and sustained gain in transferred CD62Lhi cells—is
entirely consistent with the different levels of pathology seen
following allergen challenge to the lung. A reasonable interpre-
tation of these data is that CD62Llo cells have a more advanced
differentiation status and, although PIT does not trigger their
rapid deletion through apoptosis (this appeared to occur only at
the point of later allergen challenge), PIT does impair their ef-
fector function. In contrast, and fitting the Tcm paradigm, CD62Lhi
cells are less differentiated, allowing the further TCR triggering
afforded by PIT to engender more pronounced effector function.
The observation that by the point of allergen challenge (day 26)
transferred CD62Lhi cells had gained effector function in the
absence of PIT is of interest. Whether this reflects an enrichment
of the minority of transferred cells capable of IL-5 and/or IL-13
production in the lung at day 6 or a gradual gain in this function
driven by the lung environment cannot be discerned from these
experiments, but warrants further study.
Allergen-reactive CD4+ T cells can be found in the blood of
both nonallergic and allergic individuals and are predominantly
a memory phenotype, but exhibit differences in frequency (often
higher in allergic patients) and are Th2 skewed (23, 29, 45, 46).
Lymphocytes in BAL from asthmatic patients and controls are
overwhelmingly of the memory phenotype (47). The timing of
allergen exposure could plausibly be anticipated to influence a
patient’s allergen-reactive T-cell pool. Indeed, increased frequency
of pollen-specific CD4+ T cells has been described during pollen
season whereas such fluctuation does not occur for the perennial
allergen house dust mite (29–31). Furthermore, a greater
frequency of birch-pollen reactive CD4+ Tem has been shown in
the blood of pollen allergic individuals during pollen season,
compared with a greater percentage of Tcm in house dust mite
allergic patients (29). Such clinical studies provide valuable
information, but can be limited by analysis of peripheral blood
(perhaps skewing toward Tcm rather than Tem). The existence
of lung resident memory T cells (Trm) may also mean that im-
portant changes at the site of inflammation have so far been
missed. There is increasing appreciation of the importance of
Trm to protective immunity (48, 49) and these are pre-
dominantly Tem in both mouse and man (28, 34). Trm in human
lungs are cytokine capable (34), and a contribution of such cells
to allergic disease is thought likely (28, 50, 51). Our finding that,
despite a large and durable accumulation of transferred CD62Llo
cells in the lungs of PIT-treated mice, these cells were relatively
cytokine incapable and provoked the lowest levels of AAI is
therefore reassuring and emphasizes the effectiveness of PIT on
these cells.
Clinically, there is limited information on the activation status
of T cells before, and after, immunotherapy, and there is no con-
sensus as to the most efficacious means to deliver specific immu-
notherapy, including PIT, in terms of dose, route, and frequency
(40, 52). In light of this study, it is interesting to speculate on how
currently favored regimes for delivering allergen immunotherapy,
for example multidose regimes (17, 20, 53, 54), affect the dynamics
of CD62L expression of Th2 cells and hence their behavior in re-
Fig. 7. The effects of PIT upon proliferation ofOT-II cells in the lung. Cells were transferred as described in Fig. 6. The percentage of Ki-67+ OT-II cells was assessed in
lung cell suspensions at each timepoint. Representativeplots are shownwith themedianpercentage for thegroup shown in eachpanel. Host CD4+ cellswere used to
set the threshold of positive staining (Bottom Left shows an example plot). Data are from three experiments, with three to six mice per group, per time point.
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sponse to PIT. Here we used a single PIT protocol known to be
effective against naive OT-II T cells and found it had limited
efficacy in preventing pathogenic activity of Tcm. This therefore
provides the impetus, and a tractable system, for further detailed
exploration of how different effector and memory T-cell pop-
ulations might best be controlled by different therapeutic regi-
mens. This should deliver the broadest and most robust protocols
for clinical translation.
Materials and Methods
Mice. Congenically identifiable (CD45.1) OT-II transgenic mice with an I-Ab–
restricted TCR reactive toward ovalbumin peptide 323–339 (pOVA) (35) were
maintained at the University of Edinburgh. Sex-matched C57BL/6J mice, 6–12
wk old (Charles River), were maintained on chicken egg OVA-free diets.
Experiments were conducted under a UK Home Office license and approved
by the local ethics review panel.
Antigens. OVA was obtained from Worthington Biochemical Corporation.
pOVA was synthesized by Peplogic and reconstituted using sterile water
(Sigma-Aldrich).
Th2 Polarization of OT-II Cells. Cells from spleens and lymph nodes of naive
OT-II mice were seeded at 4 × 106 cells/mL in RPMI 1640 (Gibco) with 2 mM
L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin (all from
PAA), 50 μM 2-β-mercaptoethanol, and 5% (vol/vol) heat-inactivated FCS
Fig. 8. The effects of PIT upon Th2 cytokine capabilities of transferred CD62Llo or CD62Lhi cells in the lung. Cells were transferred as described in Fig. 6. Pooled
lung samples isolated on the indicated days were cultured overnight in the presence of pOVA before intracellular staining for cytokines. (A) IL-13 and IL-5 staining
of OT-II cells (gated on CD4+CD45.1+ cells) after culture. (B) GATA-3 expression was assessed by gating on OT-II cells after overnight culture as in A (day 6). Solid
line, PIT treated; dotted line, no PIT; shaded histogram, isotype. Data are from three experiments with three to six mice, providing samples for each time point.
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(Labtech) with 40 units/mL rIL-2 (Peprotech), 4 ng/mL rIL-4 (Peprotech),
5 μg/mL anti–IL-12 (BioXcell), 5 μg/mL anti–IFN-γ (BioXcell), and 10 μg/mL
pOVA. CD4+ cells were positively selected after 96 h of culture, or from naive
mice, using CD4 (L3T4) MACS Microbeads and an autoMACS Pro Separator
(both fromMiltenyi Biotec). A total of 4 × 106 cells were adoptively transferred
to mice via the tail vein.
FACS Sorting of CD62Lhi and CD62Llo Th2 Cell Populations. Th2-polarized, CD4+-
purified OT-II cells stained with CD4 (Invitrogen; clone RM4.5), CD44 (eBioscience;
clone IM7), and CD62L (eBioscience; clone MEL-14) were sorted (BD FACSAria II)
into CD4+CD44+CD62Llo and CD4+CD44+CD62Lhi populations. A total of 2 ×
106 cells of either population were transferred i.v. to recipient mice.
Assessing Th2 OT-II Cell Function. A total of 2 × 104 per well Th2 cells [rested
for 3 d in 10 units/mL of IL-2 (Peprotech)], or naive CD4+ OT-II cells, were
cultured with 5 × 105 per well irradiated C57BL/6J splenocytes and OVA
(Worthington Biochemical Corporation) in 96-well flat-bottom plates.
Cytokines in supernatants were measured by ELISA after 72 h.
Administration of Soluble Peptides. Two days after transfer of OT-II cells,
500 μg pOVA diluted in sterile PBS (or PBS only as a control) was given i.v. via
the tail vein.
Inducing AAI. Mice were anesthetized and 50 μg of OVA (Worthington Bio-
chemical Corporation), or PBS as a control, was instilled into the trachea.
Three i.t. challenges were given 3 d apart. Mice were culled 2 d after final i.t.
instillation. In some experiments, a cohort was culled 24 h after the second
i.t. instillation to assess OT-II cell location and frequency at this time.
BAL. Lungs were lavaged with 1 mL PBS. BAL fluid was stored at −80 °C for
cytokine analysis. Cytospins of BAL cells were stained with Quick-Diff
(Gamidor Technical Services) and differentially counted at ×650 magnifica-
tion under blinded conditions (300 cells per slide).
Histological Scoring. Lungs were perfused with PBS to remove blood. In
experiments with airway challenge, the left lung lobe was tied off for flow
cytometry and removed, and the right lobe was fixed in methacarn and em-
bedded in paraffin. Sections were stained with hematoxylin and eosin (H&E) or
Periodic acid-Schiff (PAS). Slides were scored for the presence of goblet cells as
previously described (55). Average percentages of goblet cells within 10 con-
secutive small airways (less than half the width of a field at ×200 magnifica-
tion) were calculated for each slide, under experimentally blinded conditions.
Isolating Lung Cells. Lung tissue was finely chopped and incubated in colla-
genase (type I-AS; Sigma-Aldrich) solution for 45 min at 37 °C. Tissue was
disaggregated via a 20-gauge needle.
Flow Cytometry. Single-cell suspensions from spleens, lymph nodes, and lungs
were stained with LIVE/DEAD fixable cell stain (Life Technologies), CD45.1
(eBioscience; clone A20) CD4, CD44, and CD62L (as above). Foxp3 (eBioscience;
clone FJK-16a), Ki-67 (eBioscience; clone SoIA15), and GATA-3 (BD Biosciences;
clone L50-823) staining was carried out using the Foxp3/Transcription Factor
staining buffer set (eBioscience). Ki67 and GATA-3 antibodies were applied
for 30 min at room temperature whereas Foxp3 antibodies were applied for
30 min at 4 °C. GATA-3 was also assessed after overnight culture of lung cells
in the presence of 20 μg/mL pOVA.
Intracellular Cytokine Staining. Lung cells were pooled proportionately for
each group and cultured overnight in the presence of 20 μg/mL pOVA. In-
tracellular cytokine staining was carried out using the BD Cytofix/Cytoperm
kit (BD Biosciences), IL-5 (BD Biosciences; clone TRFK5), and IL-13 (eBioscience;
clone ebio13A) antibodies.
Cytokine Detection. Cytokines were detected by ELISA, using IL-5 (BD Bio-
sciences; clone TRFK5) or IL-13 (eBioscience; clone ebio13A) capture anti-
bodies and IL-5 (BD Biosciences; clone TRFK4) or IL-13 (eBioscience; clone
ebio1316H) detection antibodies. Binding was visualized using Streptavidin–
HRP (R+D Systems) and TMB (Invitrogen). Plates were read at 450 nm,
using a BioTek Synergy HT plate reader and Gen5 software (BioTek). IL-13 in
BAL fluid was detected using a FlowCytomix analyte detection system
(eBioscience).
Flow Cytometric Analysis.Data were collected using an LSR Fortessa with FACS
DIVA software (BD Biosciences) and analyzed using FlowJo software (Treestar).
Statistical Analysis. Prism 4 (Microsoft) software was used. Data were ana-
lyzed using unpaired t tests and P < 0.05 was considered significant for
all tests.
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